Edition:
United Kingdom

Alpine Immune Sciences Inc (ALPN.OQ)

ALPN.OQ on NASDAQ Stock Exchange Global Market

4.59USD
22 Jul 2019
Change (% chg)

$-0.13 (-2.75%)
Prev Close
$4.72
Open
$4.72
Day's High
$4.72
Day's Low
$4.51
Volume
2,616
Avg. Vol
2,498
52-wk High
$8.61
52-wk Low
$3.66

Latest Key Developments (Source: Significant Developments)

Alpine Immune Sciences Reports Q1 2019 Results, Provides Corporate Update
Thursday, 9 May 2019 

May 9 (Reuters) - Alpine Immune Sciences Inc ::QTRLY CASH & CASH EQUIVALENTS OF $41.4 MILLION VERSUS $10.7 MILLION AS OF PRIOR QUARTER .ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.QTRLY NET LOSS PER SHARE $0.70.EXPECTS TO HAVE SUFFICIENT CASH TO FUND OPERATIONS INTO 2021.Q1 EARNINGS PER SHARE VIEW $-0.69 -- REFINITIV IBES DATA.  Full Article

Alpine Immune Sciences Reports Q1 Results
Thursday, 9 May 2019 

May 9 (Reuters) - Alpine Immune Sciences Inc ::ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.QTRLY NET LOSS PER SHARE $0.70.EXPECTS TO HAVE SUFFICIENT CASH TO FUND OPERATIONS INTO 2021.Q1 EARNINGS PER SHARE VIEW $-0.69 -- REFINITIV IBES DATA.QTRLY CASH AND CASH EQUIVALENTS $41,437 VERSUS $10,711.  Full Article

Alpine Immune Sciences Expects To Have Sufficient Cash To Fund Operations Into 2021
Monday, 18 Mar 2019 

March 18 (Reuters) - Alpine Immune Sciences Inc ::ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2018 FINANCIAL RESULTS.ALPINE IMMUNE SCIENCES INC - AS OF DECEMBER 31, 2018, HAD CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS TOTALING $52.3 MILLION.ALPINE IMMUNE SCIENCES - EXPECT TO HAVE SUFFICIENT CASH TO FUND OPERATIONS INTO 2021.  Full Article

Alpine Immune Sciences Reports Q3 Diluted Net Loss Per Share Attributable To Common Stockholders Of $0.88
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Alpine Immune Sciences Inc ::ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.ALPINE IMMUNE SCIENCES INC QTRLY DILUTED NET LOSS PER SHAREATTRIBUTABLE TO COMMON STOCKHOLDERS $0.88.ALPINE IMMUNE SCIENCES INC - EXPECT TO HAVE SUFFICIENT CASH TO FUND OPERATIONS INTO 2020.  Full Article

Alpine Immune Sciences Qtrly Loss Per Share $0.38
Monday, 14 May 2018 

May 14 (Reuters) - Alpine Immune Sciences Inc ::ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 REVENUE $300,000 VERSUS $700,000.ALPINE IMMUNE SCIENCES - REMAIN ON TRACK TO FILE INDS FOR ALPN-101, FOR TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES IN Q4 OF THIS YEAR.QTRLY LOSS PER SHARE $0.38.  Full Article

Alpine Immune Sciences qtrly earnings per share ‍$0.18​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Alpine Immune Sciences Inc ::Alpine Immune Sciences reports corporate update and third quarter 2017 financial results.Q3 revenue $100,000 versus $700,000.Alpine Immune Sciences Inc - ‍company expects to have cash to fund operations into 2020​.Alpine Immune Sciences Inc qtrly earnings per share ‍$0.18​.  Full Article